International audienceUnderstanding the interaction between broadly neutralizing antibodies and their epitopes provides a basis for the rational design of a preventive hepatitis C virus (HCV) vaccine. CBH-2, HC-11, and HC-1 are representatives of antibodies to overlapping epitopes on E2 that mediate neutralization by blocking virus binding to CD81. To obtain insights into escape mechanisms, infectious cell culture virus, 2a HCVcc, was propagated under increasing concentrations of a neutralizing antibody to isolate escape mutants. Three escape patterns were observed with these antibodies. First, CBH-2 escape mutants that contained mutations at D431G or A439E, which did not compromise viral fitness, were isolated. Second, under the selective ...
International audienceABSTRACT Hypervariable region 1 (HVR1) (amino acids [aa] 384 to 410) on the E2...
The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry factor CD81 and is t...
International audienceCumulative evidence supports a role for neutralizing antibodies contributing t...
International audienceABSTRACT A challenge in hepatitis C virus (HCV) vaccine development is definin...
A challenge in hepatitis C virus vaccine development is defining conserved protective epitopes. A cl...
Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis ...
Hepatitis C virus (HCV) continues to spread worldwide with an annual increase of 1.75 million new in...
Effective immunization against hepatitis C virus (HCV) infections is likely to require the induction...
A challenge for hepatitis C virus (HCV) vaccine development is to define epitopes that are able to e...
The majority of broadly neutralizing antibodies to hepatitis C virus (HCV) are against conformationa...
Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis ...
The hepatitis C virus (HCV) E2 glycoprotein is a major target of the neutralizing antibody (nAb) res...
Hepatitis C virus (HCV) is a leading cause of chronic viral hepatitis, but an effective vaccine is s...
Broadly neutralizing antibodies have been associated with spontaneous clearance of the hepatitis C i...
The hepatitis C virus (HCV) E2 glycoprotein is a major target of the neutralizing antibody (nAb) res...
International audienceABSTRACT Hypervariable region 1 (HVR1) (amino acids [aa] 384 to 410) on the E2...
The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry factor CD81 and is t...
International audienceCumulative evidence supports a role for neutralizing antibodies contributing t...
International audienceABSTRACT A challenge in hepatitis C virus (HCV) vaccine development is definin...
A challenge in hepatitis C virus vaccine development is defining conserved protective epitopes. A cl...
Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis ...
Hepatitis C virus (HCV) continues to spread worldwide with an annual increase of 1.75 million new in...
Effective immunization against hepatitis C virus (HCV) infections is likely to require the induction...
A challenge for hepatitis C virus (HCV) vaccine development is to define epitopes that are able to e...
The majority of broadly neutralizing antibodies to hepatitis C virus (HCV) are against conformationa...
Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis ...
The hepatitis C virus (HCV) E2 glycoprotein is a major target of the neutralizing antibody (nAb) res...
Hepatitis C virus (HCV) is a leading cause of chronic viral hepatitis, but an effective vaccine is s...
Broadly neutralizing antibodies have been associated with spontaneous clearance of the hepatitis C i...
The hepatitis C virus (HCV) E2 glycoprotein is a major target of the neutralizing antibody (nAb) res...
International audienceABSTRACT Hypervariable region 1 (HVR1) (amino acids [aa] 384 to 410) on the E2...
The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry factor CD81 and is t...
International audienceCumulative evidence supports a role for neutralizing antibodies contributing t...